Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?
Phibro (PAHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PAHC - Phibro Animal Health Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$28.00
DETAILS
HIGH:
$49.00
LOW:
$17.00
MEDIAN:
$18.00
CONSENSUS:
$28.00
DOWNSIDE:
27.84%
Stock News
PAHC or SYK: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. HAE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Head-To-Head Survey: Tvardi Therapeutics (NASDAQ:TVRD) versus Phibro Animal Health (NASDAQ:PAHC)
Tvardi Therapeutics (NASDAQ: TVRD - Get Free Report) and Phibro Animal Health (NASDAQ: PAHC - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings. Insider and Institutional Ownership 44.7% of
Best Momentum Stocks to Buy for September 21st
SEI, SDRL and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 21st, 2026.
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Phibro Animal Health Corporation $PAHC Shares Acquired by Engineers Gate Manager LP
Engineers Gate Manager LP boosted its position in Phibro Animal Health Corporation (NASDAQ: PAHC) by 112.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 52,914 shares of the company's stock after purchasing an additional 28,052 shares during the quarter.
4 Stocks With Strong Interest Coverage to Buy as Yields Rise
DiamondRock Hospitality, Vertiv, Mueller Water Products and Phibro Animal Health stand out for strong interest coverage as Treasury yields rise.
Why Phibro Animal Health (PAHC) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. President & Chief Executive Officer, Daniel Bendheim; Chief Operating Officer, Larry Miller; and Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 15, 2026, at 1:05 PM ET at New York Marriott Marquis in New York. The live audio presentation will be available on the.
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead
Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stronger earnings and broader manufacturing reach. Vaccines, nutritional specialties, and companion-animal expansion give PAHC newer growth verticals beyond the legacy MFA franchise. Management's optimization program and Chicago Heights consolidation could improve efficiency as the acquired portfolio moves beyond integration.
Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health (NASDAQ: PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phibro Forward program. For the fiscal year ended June 30, 2026, Phibro posted
Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health NASDAQ: PAHC reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phibro Forward program.
Phibro (PAHC) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Phibro Animal Health (PAHC) Tops Q4 Earnings and Revenue Estimates
Phibro Animal Health (PAHC) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.57 per share a year ago.
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027. Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025) – Net sales of $396.7 million, an increase of $18.1 million, or 5% – Net income of $21.7 million, an increase of $4.5.
Phibro (PAHC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2026 financial results on Wednesday, August 26, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be availab.
Price Targets
Phibro Animal Health price target raised to $49 from $45 at Morgan Stanley
$49.00
(was $53.66)
Morgan Stanley
Phibro Animal Health price target raised to $34 from $26 at Morgan Stanley
$34.00
(was $38.46)
Morgan Stanley
Phibro Animal Health price target raised to $26 from $21 at Morgan Stanley
$26.00
(was $24.75)
Morgan Stanley
Phibro Animal Health price target lowered to $20 from $27 at Morgan Stanley
$20.00
(was $16.81)
Erin Wright
·
Morgan Stanley
Roth Capital Initiates Coverage On Phibro Animal Health with Buy Rating, Announces Price Target of $18
$18.00
(was $12.75)
Roth Capital
Barclays Maintains Underweight on Phibro Animal Health, Lowers Price Target to $17
$17.00
(was $14.29)
Barclays
Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Lowers Price Target to $21
$21.00
(was $16.06)
Morgan Stanley